Results 181 to 190 of about 830,526 (356)

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

Clinical Pharmacology &Therapeutics, EarlyView.
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra, Viktoriia Starokozhko, Elisabeth Bakker, Anna Maria Gerdina Pasmooij, Peter Gerardus Maria Mol   +4 more
wiley   +1 more source

Malignancy of Urinary Tract in Kidney Transplant Recipients-A Narrative Review. [PDF]

Cancers (Basel)
Małyszko SJ, Rog L, Sprangers B, Renaghan AD, Rosner MH, Stec R, Kraj L, Malyszko JS, Małyszko J.   +8 more
europepmc   +1 more source

A work-relatedness assessment in epidemiological case investigation of occupational cancers: II. Practice: an upper urinary tract cancer in a dyer

, 2020
Kihun Kim, Hyeoncheol Oh, Jungwon Kim
openalex   +1 more source

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes

Clinical Pharmacology &Therapeutics, EarlyView.
Target trial emulation of a multi‐institutional electronic health record network showed comparable cardiorenal effectiveness and safety of dapagliflozin versus empagliflozin in adults with type 2 diabetes and advanced‐stage chronic kidney disease.
Shih‐Hsuan Lin, Jia‐Jin Chen, Ching‐Chung Hsiao, Yu‐Wei Fang, Meng‐Ting Chen, Ming‐Hsien Tsai, Huang‐Yu Yang   +6 more
wiley   +1 more source

Role of Flow Cytometry in the Diagnosis of Urinary Tract Infections. [PDF]

Cureus
Trnacevic E, Trnacevic A, Mahmutovic M, Porobic Jahic H, Becirovic A, Selimovic J.   +5 more
europepmc   +1 more source

Streptozotocin induced hyperglycemia in the axolotl

Developmental Dynamics, EarlyView.
Abstract Background Diabetes is a group of diseases characterized by loss of β cell mass and/or function, resulting in hyperglycemia. With no established curative treatment, this has initiated research in β cell regeneration. Current animal models have either limited regenerative capacity (mice) or small size and evolutionary distance from humans ...
Pernille Lajer Sørensen, Anita Dittrich, Henrik Lauridsen   +2 more
wiley   +1 more source

Radiation toxicity grading after chemoradiotherapy of canine urinary tract carcinomas: Comparing VRTOG to VRTOG_v2.0 [PDF]

C Ahrens, Laura Beatrice, Valeria Meier, Carla Rohrer Bley   +3 more
openalex   +1 more source

Editorial Comment to Nocturnal polyuria and decreased serum testosterone: Is there an association in men with lower urinary tract symptoms? [PDF]

, 2013
Sae Chul Kim
openalex   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source

Urinary Tract Infections in Children - Microbiological Challenges and Mechanisms of Bacterial Resistance. [PDF]

Maedica (Bucur)
Marinescu AD, Marinescu MC, Moisa SM, Cinteza EE.   +3 more
europepmc   +1 more source